Xeltis Expands Medical Advisory Board with Leading Nephrologists

Xeltis, a Netherlands-based medtech company specializing in transformative implants, has recently announced the appointment of esteemed nephrology experts An De Vriese, MD, PhD, and Haimanot (Monnie) Wasse, MD, MPH, to its Medical Advisory Board (MAB). Both experts bring significant experience in nephrology to the company, which is currently advancing its product, aXess, a vascular access conduit for hemodialysis, through pivotal clinical trials in the EU and the US. The appointments support Xeltis's aim of addressing the limitations of existing hemodialysis options and its technology has the potential to significantly enhance patient outcomes by reducing the need for frequent and problematic reinterventions. Xeltis is backed by investors such as Ysios Capital, among others, and will benefit from the strategic and clinical guidance provided by Dr. De Vriese and Dr. Wasse as it moves towards commercialization of its groundbreaking technology.